An updated meta-analysis of randomized controlled trials (RCTs) examining continuous (CS) versus intermittent strategies (IS) of delivering systemic treatment (Tx) for untreated metastatic colorectal cancer (mCRC).

e14641 Background: The median life expectancy for unresectable mCRC is now 30 months. Traditionally, CS are used to treat mCRC; however, to reduce treatment-related toxicity, IS have been developed. Our previously published meta-analysis has now been updated with the results from the AIO KRK 07 study. Methods: A systematic review was conducted to identify RCTs comparing CS to IS. The results of identified trials were clinically homogenous, so the data were pooled using RevMan 5.3 software. Overall survival (OS) hazard ratios (HR) were extracted from the most recently presented trial results. Random effects models were used for all pooling. Results: Twelve RCTs are now identified (N=5,381), 9 with available HRs (N evaluable=5,025). In the experimental arm of these trials, the treatment given after induction included none (“chemotherapy free interval” (CFI), 5 trials, N=3,081), or a maintenance treatment: fluoropyrimidine (1 trial, N=620), or biologic (2 trials, N=852). The AIO KRK 07 trial (N=472) had two ...